Background
T2DM | Type 2 diabetes mellitus |
PCI | Percutaneous coronary intervention |
DAPT | Dual antiplatelet therapy |
TAPT | Triple antiplatelet therapy |
TVR | Target vessel revascularization |
TLR | Target lumen revascularization |
MACEs | Major adverse cardiac effects |
PRI | Platelet reactivity index |
WMD | Weight mean difference |
Methods
Eligibility and search strategy
Inclusion and exclusion criteria
Data extraction and quality assessment
Definitions, outcomes and follow-up
Statistical analysis
Results
Selected studies and baseline characteristics
Trials | No of patients (DAPT + TAPT) | Follow up period (month) | Reported endpoints/outcomes |
---|---|---|---|
Han 2009 [6] | 263 | 12 | MACEs, TVR, and ADR. |
Lee 2011 [33] | 176 | 12 | MACEs, TVR, TLR, ST, D/MI/TVR, BL and ADR. |
Lee 2008 [5] | 400 | 9 | MACEs, TVR, TLR, ST, D/MI/TVR, BL and ADR. |
Lee 2007 [34] | 166 | 9 | MACEs, TVR, TLR, ST, D/MI/TVR, BL and ADR. |
Yang 2011 [35] | 154 | – | PRU and PA |
Yang 2007 [36] | 55 | 7 | PA |
Capranzano 2012 [37] | 80 | 1 | PRU and PRI |
Angiolillo 2008 [38] | 40 | 1 | PRI and PA |
Angiolillo 2011 [39] | 106 | 1 | PRI |
Ha 2013 [40] | 84 | 2 | PRU and PA |
Study/Year | Age (yrs) | Male (%) | Ht (%) | Hc (%) | Cs (%) | Qa
|
---|---|---|---|---|---|---|
T/D | T/D | T/D | T/D | T/D | ||
Lee 2007 [34] | 60.9/61.2 | 64.8/63.6 | 54.8/55.2 | 30.0/28.4 | 37.6/37.2 | B |
Lee 2008 [5] | 61.0/60.7 | 59.0/57.0 | 59.5/59.5 | 30.5/28.5 | 24.0/31.5 | B |
Yang 2011 [35] | 63.5/63.5 | 62.3/62.3 | 55.8/55.8 | 37.7/37.7 | 28.6/28.6 | B |
Yang 2009 [36] | 63.4/63.8 | 40.0/60.0 | 61.9/57.1 | 28.6/41.2 | 14.3/20.6 | B |
Capranzano 2012 [37] | 60.4/60.4 | 60.2/60.2 | 91.2/91.2 | 97.0/97.0 | 37.1/37.1 | B |
Angiolillo 2008 [38] | 64.0/64.0 | 60.0/60.0 | 96.0/96.0 | 92.0/92.0 | 24.0/24.0 | B |
Angiolillo 2011 [39] | 60.5/60.5 | 63.0/63.0 | 95.0/95.0 | 100.0/100.0 | 28.0/28.0 | B |
Ha 2013 [40] | 64.9/62.3 | 67.7/76.1 | 71.4/76.1 | 33.3/42.5 | 23.8/23.8 | B |
Lee 2011 [33] | 60.9/62.1 | 70.0/71.5 | 58.4/64.7 | 42.4/45.0 | 30.4/30.1 | B |
Han 2009 [6] | 59.6/60.2 | 73.8/72.9 | 57.9/56.1 | 45.5/45.4 | – | B |
Variables (mm) | TAPT group (n = 377) | DAPT group (n = 365) |
---|---|---|
Reference diameter | 2.81 | 2.79 |
Lesion length | 31.5 | 31.7 |
Stented length | 37.45 | 36.05 |
Minimal lumen diameter in segment before procedure | 0.81 | 0.79 |
Minimal lumen diameter in segment after procedure | 2.25 | 2.24 |
Minimal lumen diameter in stent after procedure | 2.57 | 2.58 |
Stenosis diameter in segment before procedure (%) | 70.3 | 70.4 |
Stenosis diameter in segment after procedure (%) | 17.7 | 17.2 |
Stenosis diameter in stent after procedure (%) | 8.45 | 7.57 |
Acute gain in segment | 1.44 | 1.46 |
Acute gain in stent | 1.76 | 1.79 |